<DOC>
	<DOC>NCT00106405</DOC>
	<brief_summary>Bipolar disorder affects 2.4 million adults in the USA between the ages of 18-65 and has considerable economic impact on our society. Bipolar mania accounts for 1 in 7 psychiatric emergencies and is associated with significant morbidity and mortality. The purpose of the study is to evaluate the safety and efficacy of open-label memantine in the acute management of adults with bipolar I disorder hospitalized for mania.</brief_summary>
	<brief_title>An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Patients must have a documented clinical diagnosis of bipolar I disorder and must be currently experiencing a manic or mixed episode. Patients must be voluntarily hospitalized with a primary diagnosis of mania. Rapid cycling bipolar disorder. Suicidal risk. First manic episode. ECT, clozapine or a depot neuroleptic in the past 3 months. Substance dependence. Known HIV infection. Comorbid serious, uncontrolled systemic illness.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Bipolar I Disorder</keyword>
	<keyword>Mania</keyword>
	<keyword>Memantine HCl</keyword>
</DOC>